ReviewNutrients2021
Review in Nutrients, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- The gut microbiome axis: how Lactobacillus-fermented soymilk orchestrates health.Archives of microbiology · 2026Review
- Lactobacillus reuteri SKLAN202402ZF inhibited by early-life lincomycin exposure alleviate intestinal damage and inflammation sensitivity.Microbiome · 2026Article
- Biofilm state Limosilactobacillus reuteri modulates aryl hydrocarbon receptor activity and suppresses experimental necrotizing enterocolitis.Pediatric research · 2026Article
- Biofilms: from the cradle of life to life support.NPJ biofilms and microbiomes · 2026Review
- Surface modification of probiotics at single-cell resolution: Strategies, applications, and future directions in inflammatory bowel disease.Materials today. Bio · 2025Review
- Probiotics in Pet Food: A Decade of Research, Patents, and Market Trends.Foods (Basel, Switzerland) · 2025Review
- Effects of Biofilm Formation on Gastrointestinal Tolerance, Mucoadhesion and Transcriptomic Responses of Probiotics.Food science & nutrition · 2025Article
- Development of aApplied and environmental microbiology · 2024Article
- Region-Specific Effects of Metformin on Gut Microbiome and Metabolome in High-Fat Diet-Induced Type 2 Diabetes Mouse Model.International journal of molecular sciences · 2024Article
- Cannabidiol decreases histological intestinal injury in a neonatal experimental model of necrotizing enterocolitis.Laboratory animal research · 2024Article
- Regulatory mechanisms and applications ofFrontiers in microbiology · 2024Review
- Superior performance of biofilm versus planktonic Limosilactobacillus reuteri in protection of the intestines and brain in a piglet model of necrotizing enterocolitis.Scientific reports · 2023Article
- The Impact of Maternal Probiotics on Intestinal Vitamin D Receptor Expression in Early Life.Biomolecules · 2023Article
- Phenotypic Traits and Probiotic Functions ofFoods (Basel, Switzerland) · 2023Article
- Current and future methods of probiotic therapy for necrotizing enterocolitis.Frontiers in pediatrics · 2023Review
- The role of potential probiotic strainsFrontiers in microbiology · 2023Review
- Effects of Probiotics on Gut Microbiomes of Extremely Preterm Infants in the Neonatal Intensive Care Unit: A Prospective Cohort Study.Nutrients · 2022Article
- Review
- Biofilm-based delivery approaches and specific enrichment strategies of probiotics in the human gut.Gut microbesReview
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Necrotizing enterocolitis (NEC) is a devastating disease predominately found in premature infants that is associated with significant morbidity and mortality. Despite decades of research, medical management with broad spectrum antibiotics and bowel rest has remained relatively unchanged, with no significant improvement in patient outcomes. The etiology of NEC is multi-factorial; however, gastrointestinal dysbiosis plays a prominent role in a neonate's vulnerability to and development of NEC. Probiotics have recently emerged as a new avenue for NEC therapy. However, current delivery methods are associated with potential limitations, including the need for at least daily administration in order to obtain any improvement in outcomes. We present a novel formulation of enterally delivered probiotics that addresses the current limitations. A single enteral dose of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.